Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: Galirayo who wrote (11511)	9/6/2005 10:01:47 PM
From: robb3267	Read Replies (1) \| Respond to of 23958

Thanks Ray....take a look at this major triangle taking shape on the Dow...pattern has a major projection based on pattern measurement. stockcharts.com[w,a]dhcayiay[dd][pb50!b200!f][vc60][iub14!la12,26,9!lp14,3,3][J53361831,Y]&pref=G

To: Galirayo who wrote (11511)	9/7/2005 10:30:42 AM
From: Ken W	Read Replies (1) \| Respond to of 23958

Ray Are you ready kids? Ohhhhhhhhhhh stockcharts.com[w,a]wacayiay[df][pb50!c20!f][vc60][iut!Ua12,26,9!Uv25]&pref=G Off to work. Ken

To: Galirayo who wrote (11511)	9/7/2005 10:31:07 AM
From: ACAN	Read Replies (2) \| Respond to of 23958

Ray; CTE lots of action finally on this old fave. Maybe the shorts are being hung out. stockcharts.com[w,a]dacayiay[dc][pb50!c20!f][vc60][iut!Ua12,26,9!Uv25]&pref=G CTE 9/7/05 10:08:00 AM - CardioTech Receives FDA Clearance for Heparin-Coated Auto Transfusion and Cardiotomy Products WILMINGTON, Mass., Sept 07, 2005 /PRNewswire-FirstCall via COMTEX/ -- CardioTech International, Inc. (Amex: CTE) today announced that its wholly owned subsidiary, Gish Biomedical Inc. ("Gish") has received FDA clearance for its auto transfusion and cardiotomy reservoir products with GBS(R) Coating for the cardiopulmonary surgery market. The potential market for coated heart-lung bypass products in the U.S. is estimated at $250 million annually. The worldwide market for heart-lung products is estimated at $500 million annually. The GBS(R) (Gish Biocompatible Surface) Coating is a proprietary covalently bonded heparin based coating developed at Gish. GBS(R) is a biocompatible coating and is composed of heparin and hyaluronic acid, or hyaluronan. Hyaluronan is a hydrophilic biopolymer that occurs naturally in the human body. Because it is found in extracellular matrices, is blood compatible and lacks immunogenicity, hyaluronan is a perfect coating for blood-contacting applications. Stephen DiRocco, General Manager of Gish, stated, "We are pleased to have now received FDA clearance for the full line of cardiopulmonary products used in open heart surgery with our GBS(R) Coating. Gish sells heart-lung bypass products to over 300 hospitals worldwide. We believe the full line of GBS(R) Coated products now provides us with more opportunity to increase our market share of heparin based products. Our final objective of the GBS(R) Coating project is to gain CE marking to sell GBS(R) Coated products in the European Union. A larger percent of customers in the European Union demand coated products versus the U.S. market. We have started this process and expect completion in the first quarter of 2006." Allan